AMGEN INC. $1,000,000,000 2.200% SENIOR NOTES DUE 2027 $1,250,000,000 2.300% SENIOR NOTES DUE 2031 $750,000,000 3.150% SENIOR NOTES DUE 2040 $1,000,000,000 3.375% SENIOR NOTES DUE 2050 Underwriting AgreementUnderwriting Agreement • May 6th, 2020 • Amgen Inc • Biological products, (no disgnostic substances) • New York
Amgen Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of $1,000,000,000 additional principal amount of its existing 2.200% Senior Notes due 2027 (the “2027 Reopening Notes”), $1,250,000,000 principal amount of its 2.300% Senior Notes due 2031 (the “2031 Notes”), $750,000,000 additional principal amount of its existing 3.150% Senior Notes due 2040 (the “2040 Reopening Notes”) and $1,000,000,000 additional principal amount of its existing 3.375% Senior Notes due 2050 (the “2050 Reopening Notes,” and together with the 2027 Reopening Notes, the 2031 Notes and the 2040 Reopening Notes, the “Securities”).
